Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: A systematic review

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 7, 2011, Pages 1095-1104

  Jin, Fei ^a   Xiong, Wen Jian ^a   Jing, Jia Chen ^a   Feng, Zhen ^a   Qu, Li Shuai ^b   Shen, Xi Zhong ^b  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

False positive report probability (FPRP); Hepatocellular carcinoma (HCC); Meta analysis; Odds ratio (OR); Single nucleotide polymorphisms (SNPs); Venice guideline

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A7; HFE PROTEIN; INTERLEUKIN 1BETA; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN MDM2;

ARTICLE; CONTROLLED STUDY; FALSE POSITIVE REPORT PROBABILITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HFE GENE; HUMAN; IL 1B GENE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MDM2 GENE; MEDLINE; MNSOD GENE; PRIORITY JOURNAL; PROBABILITY; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; UGT1A7 GENE;

CARCINOMA, HEPATOCELLULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959762483     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-010-0970-0     Document Type: Article

References (66)

1. Akkiz H, Bayram S et al (2009) G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 33(3-4):261-264
2. Akkiz H, Sumbul AT et al (2010) MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol 34(4): 448-452
3. Ballardini G, Groff P et al (1994) Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 20(2):218-222 (Pubitemid 24086835)
4. Beckman LE, Hagerstrand I et al (2000) Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 59(4):317-322
5. Boige V, Castera L et al (2003) Lack of association between HFE gene mutations and hepatocellular carcinoma in patients with cirrhosis. Gut 52(8):1178-1181 (Pubitemid 36877432)
6. Borentain P, Gerolami V et al (2007) DNA-repair and carcinogen- metabolising enzymes genetic polymorphisms as an independent risk factor for hepatocellular carcinoma in Caucasian liver-transplanted patients. Eur J Cancer 43(17):2479-2486 (Pubitemid 350086929)
7. Bougeard G, Baert-Desurmont S et al (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43(6):531-533 (Pubitemid 43927330)
8. Bruzzi P, Green SB et al (1985) Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 122(5):904-914 (Pubitemid 16207356)
9. Cauza E, Peck-Radosavljevic M et al (2003) Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 98(2):442-447 (Pubitemid 36232397)
10. Chen CJ, Chen DS (2002) Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 36(5):1046-1049
11. Chen CC, Yang SY et al (2005) Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol 34(6):1310-1318
12. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860-867 (Pubitemid 36019639)
13. Dharel N, Kato N et al (2006) MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 12(16):4867-4871 (Pubitemid 44338572)
14. Dupont WD, Plummer WD Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11(2):116-128
15. Dupont WD, Plummer WD Jr (1998) Power and sample size calculations for studies involving linear regression. Control Clin Trials 19(6):589-601 (Pubitemid 29057724)
16. Egger M, Davey Smith G et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634 (Pubitemid 27387172)
17. Ellervik C, Birgens H et al (2007) Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66, 000 cases and 226, 000 controls. Hepatology 46(4):1071-1080 (Pubitemid 350144771)
18. El-Omar EM, Carrington M et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776):398-402 (Pubitemid 30164342)
19. Ezzikouri S, El Feydi AE et al (2008a) Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 649(1-2):1-6 (Pubitemid 350235309)
20. Ezzikouri S, El Feydi AE et al (2008b) Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population. Arch Med Res 39(2):236-241 (Pubitemid 350299622)
21. Ezzikouri S, El Feydi AE et al (2009) MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 32(5-6):380-385
22. Guillemette C (2003) Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics J 3(3):136-158
23. Hellerbrand C, Poppl A et al (2003) HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol 1(4):279-284 (Pubitemid 37254455)
24. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558 (Pubitemid 34746062)
25. Hsieh JK, Chan FS et al (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3(2):181-193 (Pubitemid 29292619)
26. Imaizumi T, Higaki Y et al (2009) Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population. Carcinogenesis 30(10):1729-1734
27. Ioannidis JP, Boffetta P et al (2008) Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 37(1):120-132 (Pubitemid 351228620)
28. Jin F, Qu LS et al (2009) Association between the methylenetetrahydrofolate reductase C677T polymorphism and hepatocellular carcinoma risk: a meta-analysis. Diagn Pathol 4:39
29. Jin F, Qu LS et al (2010) Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res 29:18
30. Kong SY, Ki CS et al (2008) UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers. Cancer Sci 99(2):340-344
31. Lain S, Lane D (2003) Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer 39(8):1053-1060 (Pubitemid 36555861)
32. Lau J, Ioannidis JP et al (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820-826 (Pubitemid 27465551)
33. Lauret E, Rodriguez M et al (2002) HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Am J Gastroenterol 97(4):1016-1021 (Pubitemid 34408263)
34. Leu JD, Lin IF et al (2009) Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol 15(44):5592-5597
35. Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13(1):49-58 (Pubitemid 36269180)
36. Migita K, Maeda Y et al (2007) Polymorphisms of interleukin-1beta in Japanese patients with hepatitis B virus infection. J Hepatol 46(3):381-386 (Pubitemid 46185698)
37. Nahon P, Sutton A et al (2005) Genetic dimorphism in superoxide dismutase and susceptibility to alcoholic cirrhosis, hepatocellular carcinoma, and death. Clin Gastroenterol Hepatol 3(3):292-298 (Pubitemid 40568736)
38. Nahon P, Sutton A et al (2007) Manganese superoxide dismutase dimorphism and iron overload, hepatocellular carcinoma, and death in hepatitis C virus-infected patients. Clin Gastroenterol Hepatol 5(5):630-635 (Pubitemid 46671532)
39. Nahon P, Sutton A et al (2008) Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis. Gastroenterology 134(1):102-110
40. Nahon P, Sutton A et al (2009) Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis. Hepatology 50(5):1484-1493
41. Ognjanovic S, Yuan JM et al (2009) Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis 30(5):758-762
42. Oh SS, Chang SC et al (2010) Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer 127(9):2169-2182
43. Okamoto K, Ishida C et al (2010) The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med 49(10):887-895
44. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2(9):533-543
45. Ropero P, Briceno O et al (2007) The H63D mutation in the HFE gene is related to the risk of hepatocellular carcinoma. Rev Esp Enferm Dig 99(7):376-381
46. Rossi L, Leveri M et al (2003) Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. J Hepatol 39(4):564-570 (Pubitemid 37204657)
47. Sakamoto T, Higaki Y et al (2008) Interaction between interleukin-1beta -31T/C gene polymorphism and drinking and smoking habits on the risk of hepatocellular carcinoma among Japanese. Cancer Lett 271(1):98-104
48. Shi WJ, Chen H et al (2005) Association of mutations of HFE gene and hepatocellular carcinoma following chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 13(9):682-684
49. Silvestri L, Sonzogni L et al (2003) CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 104(3):310-317 (Pubitemid 36249813)
50. Stucker I, Loriot MA et al (2007) UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers? BMC Cancer 7:214
51. Sun L, Konig IR et al (2009) Manganese superoxide dismutase (MnSOD) polymorphism, alcohol, cigarette smoking and risk of oesophageal cancer. Alcohol Alcohol 44(4):353-357
52. Sutton A, Imbert A et al (2005) The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 15(5):311-319
53. Sutton A, Nahon P et al (2006) Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res 66(5):2844-2852
54. Tanabe KK, Lemoine A et al (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299(1):53-60
55. Thakkinstian A, McElduff P et al (2005) A method for meta-analysis of molecular association studies. Stat Med 24(9):1291-1306 (Pubitemid 40585169)
56. Tseng CS, Tang KS et al (2005) UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol 100(8):1758-1763
57. Vogel A, Kneip S et al (2001) Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121(5):1136-1144 (Pubitemid 33022094)
58. Wacholder S, Chanock S et al (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96(6):434-442 (Pubitemid 38443646)
59. Wang Y, Kato N et al (2004) UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in japanese patients with hepatitis C virus infection. Clin Cancer Res 10(7):2441-2446 (Pubitemid 38445704)
60. Wang S, Wang F et al (2009) Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur J Cancer 45(16):2874-2881
61. Willis G, Bardsley V et al (2005) Hepatocellular carcinoma and the penetrance of HFE C282Y mutations: a cross sectional study. BMC Gastroenterol 5:17
62. Yoon YJ, Chang HY et al (2008) MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 29(6):1192-1196 (Pubitemid 351964880)
63. Yoshimura A (2006) Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97(6):439-447
64. Yuan JM, Lu SC et al (2007) Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology 46(3):749-758 (Pubitemid 47436121)
65. Yuan X, Zhou G et al (2008) Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 17(12):3621-3627
66. Zintzaras E, Ioannidis JP (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28(2):123-137